Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

This study found that prenatal exposure to certain pesticides may lead to earlier breast development in girls, potentially associated with higher androgen levels.

This study found no statistically significant association between the use of 5α-reductase inhibitors and male breast cancer incidence.

This case study highlights that breast cancer may present as alopecia refractory to usual treatments, indicating the need for consideration of underlying malignancy in such cases.

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.

This article summarizes the MHRA report on finasteride and does not present new clinical findings.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

This essay critically analyzes photographic narratives of breast cancer, particularly Catherine Lord's and Lynn Kohlman's works, to explore how these narratives deepen understanding of women's technologized bodies and offer discursive resistance and audience engagement.

This study found an association between dispensed finasteride and an increased risk of male breast cancer, though uncertainties around confounding factors and potential biases suggest these results should be interpreted with caution.

This study found no evidence that finasteride use is associated with an increased risk of male breast cancer.

This study found that scalp cooling significantly reduced chemotherapy-induced hair loss in breast cancer patients, especially those receiving taxane monotherapy, but did not significantly affect hair regrowth after chemotherapy.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

This study found that the epirubicin-docetaxel chemotherapy regimen for metastatic breast cancer resulted in a clinical response in 55% of patients, with maintained global quality of life despite some impairments.

Among breast cancer patients undergoing chemotherapy, this study found that anxiety and depression were present but did not affect overall quality of life.

This study reported an almost doubling of advanced breast cancer incidence in women under 40 over three decades, but its significance remains uncertain and requires further confirmation.

This case report describes a rare instance of alopecia neoplastica, where breast cancer metastasized to the scalp, which can be mistakenly diagnosed as alopecia areata.

This study found that the expression of certain biomarkers, including HER-2 and oestrogen receptor alpha, in breast skin may be influenced by the presence of breast cancer, suggesting a systemic effect.

This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This study explored a method using deep solvents in the presence of ultrasound to efficiently extract lignans from flax seeds, aiming to maximize their health benefits like hormonal balance and reduced cancer risk, while minimizing toxicity.

This study found distinct symptom clusters in women with Stage I and Stage III nonmetastatic breast cancer, revealing differences in symptom prevalence and intensity, which could guide personalized supportive care strategies to improve quality of life.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

In this study of women with breast cancer undergoing chemotherapy and scalp cooling, 12% experienced incomplete hair regrowth at 6 months, with tamoxifen therapy identified as a significant risk factor for persistent chemotherapy-induced alopecia.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Understanding breast cancer requires considering both medical advancements and social influences.

This study found that monoclonal antibodies identified distinct staining patterns in benign and malignant skin appendage tumors, highlighting their potential as markers for analyzing skin tumors.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.